These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31754998)

  • 1. mGluR5 Allosteric Modulation Promotes Neurorecovery in a 6-OHDA-Toxicant Model of Parkinson's Disease.
    Farmer K; Abd-Elrahman KS; Derksen A; Rowe EM; Thompson AM; Rudyk CA; Prowse NA; Dwyer Z; Bureau SC; Fortin T; Ferguson SSG; Hayley S
    Mol Neurobiol; 2020 Mar; 57(3):1418-1431. PubMed ID: 31754998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of BDNF/TrkB signaling in the effect of diphenyl diselenide on motor function in a Parkinson's disease rat model.
    Sampaio TB; Pinton S; da Rocha JT; Gai BM; Nogueira CW
    Eur J Pharmacol; 2017 Jan; 795():28-35. PubMed ID: 27915043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro modulation of mTOR and mGlur5 influence α-synuclein accumulation.
    Xing V; Biggar K; Ferguson SSG; Hayley S
    Mol Brain; 2024 Feb; 17(1):9. PubMed ID: 38360671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of metabotropic glutamate receptor 5 attenuates axonal degeneration in 6-hydroxydopamine-induced model of Parkinson's disease.
    Zhang JN; Huang YL; Yang HM; Wang Y; Gu L; Zhang H
    Mol Cell Neurosci; 2021 Jan; 110():103572. PubMed ID: 33248235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
    Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabotropic glutamate receptor 5 mediates the suppressive effect of 6-OHDA-induced model of Parkinson's disease on liver cancer.
    Xi SS; Bai XX; Gu L; Bao LH; Yang HM; An W; Wang XM; Zhang H
    Pharmacol Res; 2017 Jul; 121():145-157. PubMed ID: 28455267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electroacupuncture Promotes Recovery of Motor Function and Reduces Dopaminergic Neuron Degeneration in Rodent Models of Parkinson's Disease.
    Lin JG; Chen CJ; Yang HB; Chen YH; Hung SY
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28837077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective and therapeutic activity of honokiol in reversing motor deficits and neuronal degeneration in the mouse model of Parkinson's disease.
    Chen HH; Chang PC; Chen C; Chan MH
    Pharmacol Rep; 2018 Aug; 70(4):668-676. PubMed ID: 29909247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of adenosine triphosphate-sensitive potassium channels in the neuroprotective activity of hydrogen sulfide in the 6-hydroxydopamine-induced animal model of Parkinson's disease.
    Sarookhani MR; Haghdoost-Yazdi H; Sarbazi-Golezari A; Babayan-Tazehkand A; Rastgoo N
    Behav Pharmacol; 2018 Jun; 29(4):336-343. PubMed ID: 29239973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.
    Iancu R; Mohapel P; Brundin P; Paul G
    Behav Brain Res; 2005 Jul; 162(1):1-10. PubMed ID: 15922062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the antiparkinsonism and neuroprotective effects of hydrogen sulfide in acute 6-hydroxydopamine-induced animal model of Parkinson's disease: behavioral, histological and biochemical studies.
    Sarukhani M; Haghdoost-Yazdi H; Sarbazi Golezari A; Babayan-Tazehkand A; Dargahi T; Rastgoo N
    Neurol Res; 2018 Jul; 40(7):523-531. PubMed ID: 29726751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nei-like 1 inhibition results in motor dysfunction and promotes inflammation in Parkinson's disease mice model.
    Xue B; Xiao W; Tian H
    Biochem Biophys Res Commun; 2020 Jan; 521(1):245-251. PubMed ID: 31653343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y; Yoshimura R; Nakai K; Itakura T
    Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease.
    Black YD; Xiao D; Pellegrino D; Kachroo A; Brownell AL; Schwarzschild MA
    Neurosci Lett; 2010 Dec; 486(3):161-5. PubMed ID: 20854878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dramatic differences in susceptibility to l-DOPA-induced dyskinesia between mice that are aged before or after a nigrostriatal dopamine lesion.
    Bez F; Francardo V; Cenci MA
    Neurobiol Dis; 2016 Oct; 94():213-25. PubMed ID: 27312773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
    Leino S; Koski SK; Hänninen R; Tapanainen T; Rannanpää S; Salminen O
    Neuropharmacology; 2018 Aug; 138():371-380. PubMed ID: 29940207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of (-)-sesamin on 6-hydroxydopamine-induced neurotoxicity in PC12 cells and dopaminergic neuronal cells of Parkinson's disease rat models.
    Park HJ; Zhao TT; Lee KS; Lee SH; Shin KS; Park KH; Choi HS; Lee MK
    Neurochem Int; 2015; 83-84():19-27. PubMed ID: 25747493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of mTOR and CREB pathways following mGluR5 blockade contribute to improved Huntington's pathology in zQ175 mice.
    Abd-Elrahman KS; Ferguson SSG
    Mol Brain; 2019 Apr; 12(1):35. PubMed ID: 30961637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI.
    Perlbarg V; Lambert J; Butler B; Felfli M; Valabrègue R; Privat AL; Lehéricy S; Petiet A
    PLoS One; 2018; 13(9):e0202597. PubMed ID: 30188909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine.
    Przedborski S; Levivier M; Jiang H; Ferreira M; Jackson-Lewis V; Donaldson D; Togasaki DM
    Neuroscience; 1995 Aug; 67(3):631-47. PubMed ID: 7675192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.